Global Renal Cell Cancer Market 2016: What Factors are Contributing to the Increase in RCC Incidence Across the US, Japan, and five major EU Markets - Research and Markets
DUBLIN, August 11, 2016 /PRNewswire/ --
Research and Markets has announced the addition of the "Renal Cell Cancer" report to their offering.
Despite the approvals of several pipeline therapies, the renal cell cancer (RCC) market is expected to experience only moderate growth due to market saturation and the expiries of key brand patents.
This report addresses the following questions:
- What factors are contributing to the increase in RCC incidence across the US, Japan, and five major EU markets?
- What impact will the entry of PD-1 inhibitor Opdivo have on the RCC market?
- When are pipeline therapies in development for RCC expected to gain approval and what is their commercial outlook?
- How will genericization of key brands impact the overall value of the RCC market?
- Which treatment settings represent attractive targets for drug developers?
Key Topics Covered:
FORECAST: RENAL CELL CANCER
- Executive Summary
- Market Overview and Trends
- Methodology and Market Definition
- Afinitor (everolimus)
- AGS-0
- Atezolizumab
- Avastin (bevacizumab),
- Cometriq (cabozantinib)
- Inlyta (axitinib)
- Lenvima (lenvatinib)
- Nexavar (sorafenib)
- Opdivo (nivolumab)
- Sutent (sunitinib)
- Torisel (temsirolimus)
- Votrient (pazopanib)
- Primary Research Methodology
REATMENT: RENAL CELL CANCER
- Executive Summary
- Primary Research Methodology
- Disease Definition and Diagnosis
- Patient Segmentation
- Country Treatment Trees
- Current Treatment Options
- Prescribing Trends
EPIDEMIOLOGY: RENAL CELL CARCINOMA
- Executive Summary
- Sources and Methodology
- Forecast
- Epidemiologist Insight
- Strengths and Limitations
MARKETED DRUGS: RENAL CELL CANCER
- Executive Summary
- Product Overview
- Product profile: Afinitor
- Product profile: Avastin
- Product profile: Inlyta
- Product profile: Nexavar
- Product profile: Opdivo
- Product profile: Sutent
- Product profile: Torisel
- Product profile: Votrient
PIPELINE: RENAL CELL CANCER
- Executive Summary
- Clinical Pipeline Overview
- Recently Discontinued Drugs
- Target Product Profile
- Clinical Trial Design
- The Future of Treatment in Renal Cell Cancer
- Product profile (late stage): AGS-0
- Product profile (late stage): Cometriq
- Product profile (late stage): atezolizumab
APPENDIX
- Appendix: Marketed Drugs: Renal Cell Cancer
- Appendix: Pipeline: Renal Cell Cancer
For more information visit http://www.researchandmarkets.com/research/gkbx2j/renal_cell_cancer
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
Share this article